uu.seUppsala University Publications
Change search
Link to record
Permanent link

Direct link
BETA
Johannesson, Marie
Alternative names
Publications (10 of 20) Show all publications
Varelogianni, G., Oliynyk, I., Roomans, G. M. & Johannesson, M. (2010). The effect of N-acetylcysteine on chloride efflux from airway epithelial cells. Cell Biology International, 34(3), 245-252
Open this publication in new window or tab >>The effect of N-acetylcysteine on chloride efflux from airway epithelial cells
2010 (English)In: Cell Biology International, ISSN 1065-6995, E-ISSN 1095-8355, Vol. 34, no 3, p. 245-252Article in journal (Refereed) Published
Abstract [en]

Defective chloride transport in epithelial cells increases mucus viscosity and leads to recurrent infections with high oxidative stress in patients with CF (cystic fibrosis). NAC (N-acetylcysteine) is a well known mucolytic and antioxidant drug, and an indirect precursor of glutathione. Since GSNO (S-nitrosoglutathione) previously has been shown to be able to promote Cl- efflux from CF airway epithelial cells, it was investigated whether NAC also could stimulate Cl- efflux from CF and non-CF epithelial cells and through which mechanisms. CFBE (CF bronchial epithelial cells) and normal bronchial epithelial cells (16HBE) were treated with 1 mM, 5 mM, 10 mM or 15 mM NAC for 4 h at 37 degrees C. The effect of NAC on Cl- transport was measured by Cl- efflux measurements and by X-ray microanalysis. Cl- efflux from CFBE cells was stimulated by NAC in a dose-dependent manner, with 10 mM NAC causing a significant increase in Cl- efflux with nearly 80% in CFBE cells. The intracellular Cl- concentration in CFBE cells was significantly decreased up to 60% after 4 h treatment with 10 mM NAC. Moreover immunocytochemistry and Western blot experiments revealed expression of CFTR channel on CFBE cells after treatment with 10 mM NAC. The stimulation of Cl- efflux by NAC in OF airway epithelial cells may improve hydration of the mucus and thereby be beneficial for OF patients.

Keywords
airway epithelium, chloride transport, cystic fibrosis, N-acetylcysteine, Disability pension, Mortality, Methods
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:uu:diva-137758 (URN)10.1042/CBI20090007 (DOI)000277391600002 ()19947928 (PubMedID)
Available from: 2010-12-16 Created: 2010-12-15 Last updated: 2017-12-11Bibliographically approved
Döring, G., Elborn, J. S., Johannesson, M., de Jonge, H., Griese, M., Smyth, A. & Heijerman, H. (2007). Clinical trials in cystic fibrosis. Journal of Cystic Fibrosis, 6(2), 85-99
Open this publication in new window or tab >>Clinical trials in cystic fibrosis
Show others...
2007 (English)In: Journal of Cystic Fibrosis, ISSN 1569-1993, E-ISSN 1873-5010, Vol. 6, no 2, p. 85-99Article in journal (Refereed) Published
Abstract [en]

In patients with cystic fibrosis (CF), clinical trials are of paramount importance. Here, the current status of drug development in CF isdiscussed and future directions highlighted. Methods for pre-clinical testing of drugs with potential activity in CF patients including relevantanimal models are described. Study design options for phase II and phase III studies involving CF patients are provided, including requiredpatient numbers, safety issues and surrogate end point parameters for drugs, tested for different disease manifestations. Finally, regulatoryissues for licensing new therapies for CF patients are discussed, including new directives of the European Union and the structure of aEuropean clinical trial network for clinical studies involving CF patients is proposed.

Keywords
Animal models, Drug development, Drug licensing, European clinical trial network for CF, Pre-clinical drug testing, Safety issues, Surrogate end points
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:uu:diva-13924 (URN)10.1016/j.jcf.2007.02.001 (DOI)000245778900001 ()17350898 (PubMedID)
Available from: 2008-01-28 Created: 2008-01-28 Last updated: 2017-12-11Bibliographically approved
Nilsson, H., Dragomir, A., Ahlander, A., Johannesson, M. & Roomans, G. M. (2007). Effects of hyperosmotic stress on cultured airway epithelial cells. Cell and Tissue Research, 330(2), 257-269
Open this publication in new window or tab >>Effects of hyperosmotic stress on cultured airway epithelial cells
Show others...
2007 (English)In: Cell and Tissue Research, ISSN 0302-766X, E-ISSN 1432-0878, Vol. 330, no 2, p. 257-269Article in journal (Refereed) Published
Abstract [en]

Inhalation of hyperosmotic solutions (salt, mannitol) has been used in the treatment of patients with cystic fibrosis or asthma, but the mechanism behind the effect of hyperosmotic solutions is unclear. The relation between osmolarity and permeability changes was examined in an airway cell line by the addition of NaCl, NaBr, LiCl, mannitol, or xylitol (295–700 mOsm). Transepithelial resistance was measured as an indicator of the tightness of the cultures. Cell-cell contacts and morphology were investigated by immunofluorescence and by transmission electron microscopy, with lanthanum nitrate added to the luminal side of the epithelium to investigate tight junction permeability. The electrolyte solutions caused a significant decrease in transepithelial resistance from 450 mOsm upwards, when the hyperosmolar exposure was gradually increased from 295 to 700 mOsm; whereas the nonelectrolyte solutions caused a decrease in transepithelial resistance from 700 mOsm upwards. Old cultures reacted in a more rigid way compared to young cultures. Immuno-fluorescence pictures showed weaker staining for the proteins ZO-1, claudin-4, and plakoglobin in treated samples compared to the control. The ultrastructure revealed an increased number of open tight junctions as well as a disturbed morphology with increasing osmolarity, and electrolyte solutions opened a larger proportion of tight junctions than nonelectrolyte solutions. This study shows that hyperosmotic solutions cause the opening of tight junctions, which may increase the permeability of the paracellular pathway and result in increased transepithelial water transport.

Keywords
Airway epithelial cells, Hypertonic conditions, Permeability, Tight junctions, Transepithelial resistance, Cell culture
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:uu:diva-13920 (URN)10.1007/s00441-007-0482-7 (DOI)000249917000006 ()17768643 (PubMedID)
Available from: 2008-01-28 Created: 2008-01-28 Last updated: 2017-12-11Bibliographically approved
Nilsson, E., Kollberg, H., Johannesson, M., Wejåker, P.-E., Carlander, D. & Larsson, A. (2007). More than 10 years' continuous oral treatment with specific immunoglobulin Y for the prevention of Pseudomonas aeruginosa infections: a case report. Journal of Medicinal Food, 10(2), 375-378
Open this publication in new window or tab >>More than 10 years' continuous oral treatment with specific immunoglobulin Y for the prevention of Pseudomonas aeruginosa infections: a case report
Show others...
2007 (English)In: Journal of Medicinal Food, ISSN 1096-620X, E-ISSN 1557-7600, Vol. 10, no 2, p. 375-378Article in journal (Refereed) Published
Abstract [en]

Immunotherapy with specific antibodies is an alternative to antibiotics for the prevention of infections in humans and animals. We have used orally administered immunoglobulin Y (IgY) preparations, purified from eggs of hens immunized with Pseudomonas aeruginosa bacteria, to prevent pulmonary P. aeruginosa infections in a group of patients with cystic fibrosis (CF). Respiratory infections are major problems for CF patients because of the thick mucus in the airways, and chronic P. aeruginosa lung infections occur in virtually all CF patients and cause morbidity and mortality. The IgY-treated group had only 2.5 P. aeruginosa-positive sputum cultures per 100 months, and none of the IgY-treated patients became chronically colonized with P. aeruginosa. In the control group, 13.7 of the cultures per 100 months were positive for P. aeruginosa, and 24% of patients became chronically colonized with P. aeruginosa. The first enrolled patient in this study has now been treated continuously for more than 10 years. During the first 8 years she only had four P. aeruginosa-positive cultures. After 8 years she became chronically infected, but still after 10 years the bacteria have not turned mucoid. No negative side effects of IgY treatment have been noted during these 10 years. To our knowledge this is the longest treatment with specific yolk antibodies for therapeutic purposes.

Keywords
Antibody, Chicken, Cystic fibrosis, Egg, Immunoglobulin, Immunoglobulin Y, Immunotherapy, Pseudomonas aeruginosa, Yolk
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:uu:diva-13549 (URN)10.1089/jmf.2006.214 (DOI)000248224400025 ()17651078 (PubMedID)
Available from: 2008-06-02 Created: 2008-06-02 Last updated: 2017-12-11Bibliographically approved
Wexler, I. D., Johannesson, M., Edenborough, F. P., Sufian, B. S. & Kerem, E. (2007). Pregnancy and chronic progressive pulmonary disease.. American Journal of Respiratory and Critical Care Medicine, 175(4), 300-305
Open this publication in new window or tab >>Pregnancy and chronic progressive pulmonary disease.
Show others...
2007 (English)In: American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, E-ISSN 1535-4970, Vol. 175, no 4, p. 300-305Article in journal (Refereed) Published
Abstract [en]

Progressive pulmonary disease may preclude the option of pregnancy for a number of women in their child-bearing years due to the severity of the disease. For a subset of women with chronic lung disease including cystic fibrosis, pregnancy is possible, but can have a devastating effect both on the prospective mother and fetus. The potential hazards of pregnancy in cystic fibrosis or other progressive pulmonary diseases may trigger a moral conflict between physician and patient. The female patient may argue that her autonomy cannot be circumscribed and that the physician is obliged to assist her reproductive efforts. The physician can counter that his/her participation in potentially harmful interventions is not consistent with professional norms requiring adherence to the principles of beneficence and nonmaleficence. Whenever possible, the ethical conflict between physician and patient should be resolved before initiation of pregnancy. We propose that this best be done through structured negotiations between physician and patient with the goal of constructing an ethical framework for reducing the moral tension between the two. Steps in the negotiating process include defining the therapeutic alliance, information exchange, dialog, and deliberation. As part of the information exchange, it is important to discuss alternatives to pregnancy such as adoption and surrogacy, especially when there are strong contraindications to pregnancy. If negotiations reach a satisfactory conclusion for both sides, there should be a well-delineated consensual agreement to commence the pregnancy with the full support of the medical team.

Keywords
Chronic Disease, Conflict (Psychology), Female, Humans, Lung Diseases/*complications, Morals, Personal Autonomy, Physician-Patient Relations, Pregnancy, Pregnancy; High-Risk
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:uu:diva-13922 (URN)10.1164/rccm.200605-598OE (DOI)17110647 (PubMedID)
Available from: 2008-01-28 Created: 2008-01-28 Last updated: 2017-12-11Bibliographically approved
Johannesson, M., Vebert Olesen, H., Mehta, G. & Mehta, A. (2007). Settin up a European registry for Cystic fibrosis -Lessons Learned. : European Respiratory Disease
Open this publication in new window or tab >>Settin up a European registry for Cystic fibrosis -Lessons Learned
2007 (English)Report (Other (popular scientific, debate etc.))
Place, publisher, year, edition, pages
European Respiratory Disease, 2007. p. 25-26
Identifiers
urn:nbn:se:uu:diva-13929 (URN)
Available from: 2008-01-28 Created: 2008-01-28
Johannesson, M. & Berglund, E. G. (2007). [The Medical Products Agency's preparations prior to the new EU regulation on children and drugs]. : Läkartidningen, Nr 28-29, vol. 104
Open this publication in new window or tab >>[The Medical Products Agency's preparations prior to the new EU regulation on children and drugs]
2007 (Swedish)Other (Other (popular scientific, debate etc.))
Place, publisher, year, pages
Läkartidningen, Nr 28-29, vol. 104, 2007. p. 2099-2099
Keywords
Child, Clinical Trials as Topic, Drug Approval, Drug Labeling, Drug and Narcotic Control, European Union, Humans, Pediatrics, Pharmaceutical Preparations/administration & dosage/adverse effects
Identifiers
urn:nbn:se:uu:diva-13921 (URN)17702388 (PubMedID)
Available from: 2008-01-28 Created: 2008-01-28
Kozlova, I., Vanthanouvong, V., Johannesson, M. & Roomans, G. M. (2006). Composition of airway surface liquid determined by X-ray microanalysis.. Ups J Med Sci, 111(1), 137-53
Open this publication in new window or tab >>Composition of airway surface liquid determined by X-ray microanalysis.
2006 (English)In: Ups J Med Sci, ISSN 0300-9734, Vol. 111, no 1, p. 137-53Article in journal (Refereed) Published
Keywords
Animals, Chlorine/analysis, Comparative Study, Cystic Fibrosis/*diagnosis/genetics, Electron Probe Microanalysis/*methods, Epithelial Cells/chemistry/cytology, Female, Humans, Ions/analysis, Male, Mice, Mice; Inbred CFTR, Nasal Lavage Fluid/*chemistry/cytology, Potassium/analysis, Rats, Rats; Sprague-Dawley, Research Support; Non-U.S. Gov't, Respiratory Mucosa/*secretion, Sodium/analysis, Swine, Trachea/radiography
Identifiers
urn:nbn:se:uu:diva-20082 (URN)16553253 (PubMedID)
Available from: 2008-06-28 Created: 2008-06-28 Last updated: 2011-01-11
Vanthanouvong, V., Kozlova, I., Johannesson, M., Nääs, E., Nordvall, L., Dragomir, A. & Roomans, G. M. (2006). Composition of nasal airway surface liquid in cystic fibrosis and other airway diseases determined by X-ray microanalysis.. Microsc Res Tech, 69(4), 271-6
Open this publication in new window or tab >>Composition of nasal airway surface liquid in cystic fibrosis and other airway diseases determined by X-ray microanalysis.
Show others...
2006 (English)In: Microsc Res Tech, ISSN 1059-910X, Vol. 69, no 4, p. 271-6Article in journal (Refereed) Published
Keywords
Adolescent, Adult, Body Fluids/*chemistry, Child, Chlorine/analysis, Cystic Fibrosis/*metabolism, Electron Probe Microanalysis, Female, Heterozygote, Humans, Kartagener Syndrome/*metabolism, Male, Middle Aged, Nasal Lavage Fluid/*chemistry, Nasal Mucosa/*chemistry, Potassium/analysis, Research Support; Non-U.S. Gov't, Rhinitis/*metabolism, Salts/analysis, Sex Factors, Sodium/analysis
Identifiers
urn:nbn:se:uu:diva-19185 (URN)16586482 (PubMedID)
Available from: 2007-02-28 Created: 2007-02-28 Last updated: 2011-01-11
Roomans, G. M., Ivanovs, A., Shebani, E. B. & Johannesson, M. (2006). Transmission electron microscopy in the diagnosis of primary ciliary dyskinesia.. Ups J Med Sci, 111(1), 155-68
Open this publication in new window or tab >>Transmission electron microscopy in the diagnosis of primary ciliary dyskinesia.
2006 (English)In: Ups J Med Sci, ISSN 0300-9734, Vol. 111, no 1, p. 155-68Article in journal (Refereed) Published
Keywords
Cilia/*ultrastructure, Humans, Kartagener Syndrome/*diagnosis/genetics, Microscopy; Electron; Transmission
Identifiers
urn:nbn:se:uu:diva-20085 (URN)16553254 (PubMedID)
Available from: 2007-02-14 Created: 2007-02-14 Last updated: 2011-01-11
Organisations

Search in DiVA

Show all publications